{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T09:13:57Z","timestamp":1783329237301,"version":"3.54.6"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100018573","name":"Istanbul Medeniyet University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018573","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Circuit survival (CS) is critical for the maintenance of continuous kidney replacement therapy (CKRT). Regional citrate anticoagulation (RCA) is widely used, effective, and relatively safe; however, it is associated with complications such as citrate accumulation (CA). We aimed to analyze how a lower citrate infusion dose (CID) protocol could impact CS and risks for CA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective single-center cohort study compared the efficacy and safety of standard CID (3.0\u00a0mmol\/L) and low CID (2.2\u20132.5\u00a0mmol\/L) at initial administration in patients receiving RCA for CKRT in a pediatric intensive care unit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 127 patients received 239 circuits (115 circuits in 55 recipients of standard CID, and 124 filters in 72 recipients of low CID). When filter life was limited to 72\u00a0h, median CS for all filters was similar between the standard and low CID groups (51.0\u00a0h [IQR: 25.0\u201372.0] vs. 49.5\u00a0h [IQR: 24.0\u201372.0];\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.857). CS was also similar in circuits terminated due to clotting (standard CID: 38.0\u00a0h [IQR: 20.0\u201358.0], low CID: 37.5\u00a0h [IQR: 18.0\u201355.0]). Recipients of the low CID protocol had significantly lower frequencies of metabolic alkalosis, CA, and hypocalcemia. Multivariate regression identified two independent CA risk factors: longer circuit runtime (OR 1.013, 95% CI 1.002\u20131.025) and higher weight-adjusted blood flow rates (OR 1.208, 95% CI 1.022\u20131.427).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Administering a low CID when initializing RCA significantly reduces the likelihood of citrate-related complications while maintaining anticoagulant efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-026-07234-5","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:35:00Z","timestamp":1773110100000},"page":"2635-2645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and efficacy of low-dose initial citrate infusion for continuous kidney replacement therapy in critically ill children"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7892-2927","authenticated-orcid":false,"given":"Muhterem","family":"Duyu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0973-8098","authenticated-orcid":false,"given":"Ay\u015fe","family":"A\u015f\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"7234_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1053\/j.ajkd.2013.08.018","volume":"63","author":"SK Sethi","year":"2014","unstructured":"Sethi SK, Bunchman T, Raina R, Kher V (2014) Unique considerations in renal replacement therapy in children: core curriculum 2014. Am J Kidney Dis 63:329\u2013345. https:\/\/doi.org\/10.1053\/j.ajkd.2013.08.018","journal-title":"Am J Kidney Dis"},{"key":"7234_CR2","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1007\/s00467-011-2080-x","volume":"27","author":"SM Sutherland","year":"2012","unstructured":"Sutherland SM, Alexander SR (2012) Continuous renal replacement therapy in children. Pediatr Nephrol 27:2007\u20132016. https:\/\/doi.org\/10.1007\/s00467-011-2080-x","journal-title":"Pediatr Nephrol"},{"key":"7234_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00134-015-3807-0","volume":"41","author":"C Ronco","year":"2015","unstructured":"Ronco C, Ricci Z (2015) Pediatric continuous renal replacement: 20 years later. Intensive Care Med 41:985\u2013993. https:\/\/doi.org\/10.1007\/s00134-015-3807-0","journal-title":"Intensive Care Med"},{"key":"7234_CR4","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41390-024-03163-x","volume":"96","author":"SK Atis","year":"2024","unstructured":"Atis SK, Duyu M, Karakaya Z, Yilmaz A (2024) Citrate anticoagulation and systemic heparin anticoagulation during continuous renal replacement therapy among critically-ill children. Pediatr Res 96:702\u2013712. https:\/\/doi.org\/10.1038\/s41390-024-03163-x","journal-title":"Pediatr Res"},{"key":"7234_CR5","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1053\/j.ajkd.2011.11.030","volume":"59","author":"MY Wu","year":"2012","unstructured":"Wu MY, Hsu YH, Bai CH, Lin YF, Wu CH, Tam KW (2012) Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: a meta-analysis of randomized controlled trials. Am J Kidney Dis 59:810\u2013818. https:\/\/doi.org\/10.1053\/j.ajkd.2011.11.030","journal-title":"Am J Kidney Dis"},{"key":"7234_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11113121","volume":"11","author":"E Buccione","year":"2022","unstructured":"Buccione E, Bambi S, Rasero L, Tofani L, Piazzini T, Della Pelle C, El Aoufy K, Ricci Z, Romagnoli S, Villa G (2022) Regional citrate anticoagulation and systemic anticoagulation during pediatric continuous renal replacement therapy: a systematic literature review. J Clin Med 11:3121. https:\/\/doi.org\/10.3390\/jcm11113121","journal-title":"J Clin Med"},{"key":"7234_CR7","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/aor.13619","volume":"44","author":"V Persic","year":"2020","unstructured":"Persic V, Vajdic Trampuz B, Medved B, Pavcnik M, Ponikvar R, Gubensek J (2020) Regional citrate anticoagulation for continuous renal replacement therapy in newborns and infants: focus on citrate accumulation. Artif Organs 44:497\u2013503. https:\/\/doi.org\/10.1111\/aor.13619","journal-title":"Artif Organs"},{"key":"7234_CR8","doi-asserted-by":"publisher","first-page":"3835","DOI":"10.1007\/s00467-023-05994-y","volume":"38","author":"A Cappoli","year":"2023","unstructured":"Cappoli A, Labbadia R, Antonucci L, Bottari G, Rossetti E, Guzzo I (2023) A simplified protocol of regional citrate anticoagulation with phosphate-containing solutions in infants and children treated with continuous kidney replacement therapy. Pediatr Nephrol 38:3835\u20133844. https:\/\/doi.org\/10.1007\/s00467-023-05994-y","journal-title":"Pediatr Nephrol"},{"key":"7234_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-023-04519-1","volume":"27","author":"Z Zhou","year":"2023","unstructured":"Zhou Z, Liu C, Yang Y, Wang F, Zhang L, Fu P (2023) Anticoagulation options for continuous renal replacement therapy in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Crit Care 27:222. https:\/\/doi.org\/10.1186\/s13054-023-04519-1","journal-title":"Crit Care"},{"key":"7234_CR10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/1744-9987.13850","volume":"26","author":"R Li","year":"2022","unstructured":"Li R, Gao X, Zhou T, Li Y, Wang J, Zhang P (2022) Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis of randomized controlled trials. Ther Apher Dial 26:1086\u20131097. https:\/\/doi.org\/10.1111\/1744-9987.13850","journal-title":"Ther Apher Dial"},{"key":"7234_CR11","doi-asserted-by":"publisher","first-page":"e216","DOI":"10.1097\/PCC.0000000000003661","volume":"26","author":"HS Kihtir","year":"2025","unstructured":"Kihtir HS, Duyu M, Mementoglu ME, Tolunay I, Kendirli T, Ekinci F, Botan E, Ongun EA, Asik A, Gun E, Ucmak H, Sevketoglu E, Yildizdas D (2025) Citrate anticoagulation in continuous renal replacement therapy: multicenter PICU study of filter-related outcomes. Pediatr Crit Care Med 26:e216\u2013e226. https:\/\/doi.org\/10.1097\/PCC.0000000000003661","journal-title":"Pediatr Crit Care Med"},{"key":"7234_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/0391398819893382","volume":"43","author":"G S\u0131k","year":"2020","unstructured":"S\u0131k G, Demirbuga A, Annayev A, Citak A (2020) Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill children. Int J Artif Organs 43:234\u2013241. https:\/\/doi.org\/10.1177\/0391398819893382","journal-title":"Int J Artif Organs"},{"key":"7234_CR13","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1111\/1744-9987.12456","volume":"20","author":"A Musielak","year":"2016","unstructured":"Musielak A, Warzywoda A, Wojtalik M, Koci\u0144ski B, Kroll P, Ostalska-Nowicka D, Zachwieja J (2016) Outcomes of continuous renal replacement therapy with regional citrate anticoagulation in small children after cardiac surgery: experience and protocol from a single center. Ther Apher Dial 20:639\u2013644. https:\/\/doi.org\/10.1111\/1744-9987.12456","journal-title":"Ther Apher Dial"},{"key":"7234_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00467-016-3544-9","volume":"32","author":"MP Rico","year":"2017","unstructured":"Rico MP, Fern\u00e1ndez Sarmiento J, Rojas Velasquez AM, Gonz\u00e1lez Chaparro LS, Gastelbondo Amaya R, Mulett Hoyos H, Tibaduiza D, Quintero G\u00f3mez AM (2017) Regional citrate anticoagulation for continuous renal replacement therapy in children. Pediatr Nephrol 32:703\u2013711. https:\/\/doi.org\/10.1007\/s00467-016-3544-9","journal-title":"Pediatr Nephrol"},{"key":"7234_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189745","volume":"12","author":"MJ Brain","year":"2017","unstructured":"Brain MJ, Roodenburg OS, McNeil J (2017) Comparison of pre-filter and post-filter ionised calcium monitoring in continuous veno-venous hemodiafiltration (CVVHDF) with citrate anti-coagulation. PLoS One 12:e0189745. https:\/\/doi.org\/10.1371\/journal.pone.0189745","journal-title":"PLoS One"},{"key":"7234_CR16","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1093\/ndt\/gfq575","volume":"26","author":"GR Hetzel","year":"2011","unstructured":"Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, Isgro F, Kribben A, Himmele R, Grabensee B, Rump LC (2011) Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant 26:232\u2013239. https:\/\/doi.org\/10.1093\/ndt\/gfq575","journal-title":"Nephrol Dial Transplant"},{"key":"7234_CR17","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/nep.13656","volume":"25","author":"CB Poh","year":"2020","unstructured":"Poh CB, Tan PC, Kam JW, Siau C, Lim NL, Yeon W, Cui HH, Ding HT, Song XY, Yan P, Chea KL, Liu JS, Chionh CY (2020) Regional citrate anticoagulation for continuous renal replacement therapy - a safe and effective low-dose protocol. Nephrology 25:305\u2013313. https:\/\/doi.org\/10.1111\/nep.13656","journal-title":"Nephrology"},{"key":"7234_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae187","volume":"17","author":"A Post","year":"2024","unstructured":"Post A, Heijkoop \u00c8RH, Diebels LLM, Post A, van Meurs M, van der Voort PHJ, Franssen CFM, Volbeda M (2024) Further improvement of circuit survival in citrate based continuous renal replacement therapy. Clin Kidney J 17:sfae187. https:\/\/doi.org\/10.1093\/ckj\/sfae187","journal-title":"Clin Kidney J"},{"key":"7234_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2215\/CJN.00040505","volume":"1","author":"AJ Tolwani","year":"2006","unstructured":"Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM (2006) A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol 1:79\u201387. https:\/\/doi.org\/10.2215\/CJN.00040505","journal-title":"Clin J Am Soc Nephrol"},{"key":"7234_CR20","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1097\/CCM.0000000000001004","volume":"43","author":"DJ Gattas","year":"2015","unstructured":"Gattas DJ, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R (2015) A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Crit Care Med 43:1622\u20131629. https:\/\/doi.org\/10.1097\/CCM.0000000000001004","journal-title":"Crit Care Med"},{"key":"7234_CR21","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00467-001-0791-0","volume":"17","author":"TE Bunchman","year":"2002","unstructured":"Bunchman TE, Maxvold NJ, Barnett J, Hutchings A, Benfield MR (2002) Pediatric hemofiltration: normocarb dialysate solution with citrate anticoagulation. Pediatr Nephrol 17:150\u2013154. https:\/\/doi.org\/10.1007\/s00467-001-0791-0","journal-title":"Pediatr Nephrol"},{"key":"7234_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s00467-003-1328-5","volume":"19","author":"N Elhanan","year":"2004","unstructured":"Elhanan N, Skippen P, Nuthall G, Krahn G, Seear M (2004) Citrate anticoagulation in pediatric continuous venovenous hemofiltration. Pediatr Nephrol 19:208\u2013212. https:\/\/doi.org\/10.1007\/s00467-003-1328-5","journal-title":"Pediatr Nephrol"},{"key":"7234_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.696798","volume":"9","author":"E Buccione","year":"2021","unstructured":"Buccione E, Guzzi F, Colosimo D, Tedesco B, Romagnoli S, Ricci Z, L\u2019Erario M, Villa G (2021) Continuous renal replacement therapy in critically ill children in the Pediatric Intensive Care Unit: a retrospective analysis of real-life prescriptions, complications, and outcomes. Front Pediatr 9:696798. https:\/\/doi.org\/10.3389\/fped.2021.696798","journal-title":"Front Pediatr"},{"key":"7234_CR24","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1097\/PCC.0000000000002305","volume":"21","author":"G Cortina","year":"2020","unstructured":"Cortina G, McRae R, Chiletti R, Butt W (2020) The effect of patient- and treatment-related factors on circuit lifespan during continuous renal replacement therapy in critically ill children. Pediatr Crit Care Med 21:578\u2013585. https:\/\/doi.org\/10.1097\/PCC.0000000000002305","journal-title":"Pediatr Crit Care Med"},{"key":"7234_CR25","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1159\/000102081","volume":"156","author":"I Baldwin","year":"2007","unstructured":"Baldwin I (2007) Factors affecting circuit patency and filter \u2018life.\u2019 Contrib Nephrol 156:178\u2013184. https:\/\/doi.org\/10.1159\/000102081","journal-title":"Contrib Nephrol"},{"key":"7234_CR26","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1007\/s00134-015-4099-0","volume":"41","author":"M Bai","year":"2015","unstructured":"Bai M, Zhou M, He L, Ma F, Li Y, Yu Y, Wang P, Li L, Jing R, Zhao L, Sun S (2015) Citrate versus heparin anticoagulation for continuous renal replacement therapy: an updated meta-analysis of RCTs. Intensive Care Med 41:2098\u20132110. https:\/\/doi.org\/10.1007\/s00134-015-4099-0","journal-title":"Intensive Care Med"},{"key":"7234_CR27","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.clnu.2019.02.034","volume":"39","author":"J Jonckheer","year":"2020","unstructured":"Jonckheer J, Spapen H, Malbrain MLNG, Oschima T, De Waele E (2020) Energy expenditure and caloric targets during continuous renal replacement therapy under regional citrate anticoagulation. A viewpoint. Clin Nutr 39:353\u2013357.\u00a0https:\/\/doi.org\/10.1016\/j.clnu.2019.02.034","journal-title":"Clin Nutr"},{"key":"7234_CR28","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12882-024-03659-y","volume":"25","author":"T Dimski","year":"2024","unstructured":"Dimski T, Brandenburger T, Vollmer C, Kindgen-Milles D (2024) A safe and effective protocol for postdilution hemofiltration with regional citrate anticoagulation. BMC Nephrol 25:218. https:\/\/doi.org\/10.1186\/s12882-024-03659-y","journal-title":"BMC Nephrol"},{"key":"7234_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/786301","volume":"2014","author":"SN Fern\u00e1ndez","year":"2014","unstructured":"Fern\u00e1ndez SN, Santiago MJ, L\u00f3pez-Herce J, Garc\u00eda M, Del Castillo J, Alcaraz AJ, Bell\u00f3n JM (2014) Citrate anticoagulation for CKRT in children: comparison with heparin. Biomed Res Int 2014:786301. https:\/\/doi.org\/10.1155\/2014\/786301","journal-title":"Biomed Res Int"},{"key":"7234_CR30","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1007\/s00467-017-3694-4","volume":"32","author":"PAMA Raymakers-Janssen","year":"2017","unstructured":"Raymakers-Janssen PAMA, Lilien M, van Kessel IA, Veldhoen ES, van W\u00f6sten- Asperen RM, van Gestel JPJ (2017) Citrate versus heparin anticoagulation in continuous renal replacement therapy in small children. Pediatr Nephrol 32:1971\u20131978.\u00a0https:\/\/doi.org\/10.1007\/s00467-017-3694-4","journal-title":"Pediatr Nephrol"},{"key":"7234_CR31","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1159\/000381662","volume":"39","author":"B Wu","year":"2015","unstructured":"Wu B, Zhang K, Xu B, Ji D, Liu Z, Gong D (2015) Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purif 39:306\u2013312. https:\/\/doi.org\/10.1159\/000381662","journal-title":"Blood Purif"},{"key":"7234_CR32","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.1097\/PCC.0000000000000860","volume":"17","author":"T Zaoral","year":"2016","unstructured":"Zaoral T, Hlad\u00edk M, Zapletalov\u00e1 J, Tr\u00e1vn\u00ed\u010dek B, Gelnarov\u00e1 E (2016) Circuit lifetime with citrate versus heparin in pediatric continuous venovenous hemodialysis. Pediatr Crit Care Med 17:e399\u2013e405. https:\/\/doi.org\/10.1097\/PCC.0000000000000860","journal-title":"Pediatr Crit Care Med"},{"key":"7234_CR33","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s00467-002-0963-6","volume":"17","author":"V Chadha","year":"2002","unstructured":"Chadha V, Garg U, Warady BA, Alon US (2002) Citrate clearance in children receiving continuous venovenous renal replacement therapy. Pediatr Nephrol 17:819\u2013824. https:\/\/doi.org\/10.1007\/s00467-002-0963-6","journal-title":"Pediatr Nephrol"},{"key":"7234_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/cc11645","volume":"16","author":"HM van Oudemans- Straaten","year":"2012","unstructured":"van Oudemans- Straaten HM, Ostermann M (2012) Bench-to-bedside review: citrate for continuous renal replacement therapy, from science to practice. Crit Care 16:249. https:\/\/doi.org\/10.1186\/cc11645","journal-title":"Crit Care"},{"key":"7234_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182134","volume":"12","author":"K Rodriguez","year":"2017","unstructured":"Rodriguez K, Srivaths PR, Tal L, Watson MN, Riley AA, Himes RW, Desai MS, Braun MC, Akcan Arikan A (2017) Regional citrate anticoagulation for continuous renal replacement therapy in pediatric patients with liver failure. PLoS One 12:e0182134. https:\/\/doi.org\/10.1371\/journal.pone.0182134","journal-title":"PLoS One"},{"key":"7234_CR36","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1097\/00003246-200104000-00010","volume":"29","author":"HU Meier-Kriesche","year":"2001","unstructured":"Meier-Kriesche HU, Gitomer J, Finkel K, DuBose T (2001) Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med 29:748\u2013752. https:\/\/doi.org\/10.1097\/00003246-200104000-00010","journal-title":"Crit Care Med"},{"key":"7234_CR37","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jama.2020.18618","volume":"324","author":"A Zarbock","year":"2020","unstructured":"Zarbock A, K\u00fcllmar M, Kindgen-Milles D, Wempe C, Gerss J, Brandenburger T, Dimski T, Tyczynski B, Jahn M, M\u00fclling N, Mehrl\u00e4nder M, Rosenberger P, Marx G, Simon TP, Jaschinski U, Deetjen P, Putensen C, Schewe JC, Kluge S, Jarczak D, RICH Investigators and the Sepnet Trial Group (2020) Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. JAMA 324:1629\u20131639. https:\/\/doi.org\/10.1001\/jama.2020.18618","journal-title":"JAMA"},{"key":"7234_CR38","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcrc.2013.10.015","volume":"29","author":"D Khadzhynov","year":"2014","unstructured":"Khadzhynov D, Schelter C, Lieker I, Mika A, Staeck O, Neumayer HH, Peters H, Slowinski T (2014) Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation. J Crit Care 29:265\u2013271. https:\/\/doi.org\/10.1016\/j.jcrc.2013.10.015","journal-title":"J Crit Care"},{"key":"7234_CR39","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1097\/PCC.0000000000002993","volume":"23","author":"JM Liet","year":"2022","unstructured":"Liet JM, Baleine J, Demaret P, Mounier S, Porcheret F, Joram N, Chenouard A (2022) Semiautomated regional citrate anticoagulation for continuous kidney replacement therapy: an observational study in young children. Pediatr Crit Care Med 23:e429\u2013e433. https:\/\/doi.org\/10.1097\/PCC.0000000000002993","journal-title":"Pediatr Crit Care Med"},{"issue":"1","key":"7234_CR40","first-page":"91","volume":"7","author":"D Demirkol","year":"2020","unstructured":"Demirkol D, Karap\u0131nar B, Dursun O, Arslank\u00f6yl\u00fc AE, Besli GE, Duman M, Kendirli T, K\u00f6ro\u011flu TF, Saz U, \u015eevketo\u011flu E, Y\u0131lmaz HL, Tuygun N, Y\u0131ld\u0131zda\u015f D (2020) T\u00fcrkiye\u2019de s\u00fcrekli renal destek sistemleri uygulanan kritik \u00e7ocuk hastalara y\u00f6nelik protokol. J Pediatr Emerg Intensive Care Med 7:91\u2013115","journal-title":"J Pediatr Emerg Intensive Care Med"},{"issue":"9","key":"7234_CR41","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1007\/s00134-024-07531-3","volume":"50","author":"PM Honor\u00e9","year":"2024","unstructured":"Honor\u00e9 PM, Rimmel\u00e9 T, Joannes-Boyau O (2024) Citrate anticoagulation for continuous renal replacement therapy. Intensive Care Med 50:1553\u20131556. https:\/\/doi.org\/10.1007\/s00134-024-07531-3","journal-title":"Intensive Care Med"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07234-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T08:14:09Z","timestamp":1783325649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07234-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7234"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07234-5","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}